{
    "nct_id": "NCT04083599",
    "official_title": "A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors",
    "inclusion_criteria": "Monotherapy - Dose Escalation and Dose Expansion Parts\n\n* Participants with non-CNS solid tumors that is metastatic or unresectable and for whom there is no available standard therapy.\n* Participants with a confirmed diagnosis of relapsed or refractory, advanced and/or metastatic melanoma, NSCLC, or CRC and for whom there is no available standard therapy\n\nCombination Therapy - Dose Expansion Part\n\n* Participants with unresectable Stage III or Stage IV melanoma with no prior systemic anticancer therapy for unresectable or metastatic disease. Primary ocular or mucosal melanoma is excluded.\n* Participants with Stage IV metastatic or recurrent NSCLC with no prior systemic anticancer therapy, no actionable mutation.\n* Participants with recurrent or metastatic HNSCC with no prior systemic therapy administered in the recurrent or metastatic setting.\n* Participants with confirmed metastatic PDAC with no previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease.\n\nGeneral (all phases):\n\n* Must be age ≥ 18 years of age on the day of signing informed consent, or the legal age of consent in the jurisdiction in which the trial is taking place.\n* Measurable disease according to RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) 0-1\n* Normal or adequate liver, renal, cardiac and bone marrow function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Monotherapy - Dose Escalation and Dose Expansion Parts\n\n* Treatment with an anti-cancer agent (within 21 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1042 administration\n* Radiotherapy within 14 days prior to first GEN1042 administration\n* Toxicities from previous anti-cancer therapies that have not resolved\n\nCombination Therapy - Dose Expansion Part\n\n* Has received prior systemic cytotoxic chemotherapy, biological therapy, OR major surgery within 3 weeks or at least 5 half-lives of the drug (whichever is shorter) of the first dose of trial treatment.\n* Radiotherapy within 14 days of start of trial treatment or received lung radiation therapy of > 30 Gy within 6 months of the first dose of trial treatment.\n\nGeneral (all phases)\n\n* Participants has an active, known, or suspected autoimmune disease.\n* History of non-infectious pneumonitis that required steroids or currently has pneumonitis.\n* History of ≥ grade 3 allergic reactions to monoclonal antibody (mAb) therapy\n* Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}